Understanding the Benefits of a Water-Soluble Compound from Poria Cocos

Jenn Hoskins
13th June, 2024

Understanding the Benefits of a Water-Soluble Compound from Poria Cocos

Image Source: Natural Science News, 2024

Key Findings

  • Researchers at Hebei Agricultural University studied a polysaccharide from Poria cocos (PCP) as a new vaccine adjuvant
  • PCP was found to activate immune cells and stimulate both antibody (humoral) and T cell (cellular) responses
  • Unlike traditional Alum adjuvants, PCP enhanced the cellular immune response, making it promising for vaccines against chronic diseases and cancers
Adjuvants are critical components of vaccines that enhance the immune response to the antigen, ensuring that the body mounts a strong and lasting defense against pathogens. However, traditional adjuvants like aluminum salts (commonly referred to as Alum) primarily stimulate a humoral immune response, which involves the production of antibodies. This type of response is effective against many pathogens but falls short in combating chronic infectious diseases and cancers, which require a robust cellular immune response involving T cells. The need for adjuvants that can stimulate both humoral and cellular immunity has led researchers to explore new materials, including polysaccharides. A recent study conducted by Hebei Agricultural University explored the potential of a polysaccharide isolated from Poria cocos, referred to as PCP, as a novel vaccine adjuvant[1]. This study is significant because it addresses the limitations of Alum adjuvants by demonstrating that PCP can induce both humoral and cellular immune responses. PCP is a water-soluble polysaccharide with a molecular weight of 20.112 kDa. Its structure primarily consists of →6)-α-D-Galp-(1→, with smaller amounts of →3)-β-D-Glcp-(1→ and →4)-β-D-Glcp-(1→. The researchers found that PCP promoted the activation of dendritic cells (DCs) and macrophages in vitro. These cells are crucial for initiating and regulating immune responses. When used as an adjuvant with ovalbumin (a model antigen), PCP facilitated the activation of DCs in lymph nodes and evoked a strong antibody response that included both Th1 and Th2 immune responses. Th1 responses are associated with cellular immunity, while Th2 responses are linked to humoral immunity. The study's findings are particularly noteworthy when compared to the effects of Alum adjuvants. While Alum is effective at inducing a strong antibody response, it does not significantly stimulate cellular immunity. In contrast, PCP not only induced a potent antibody response but also markedly enhanced the cellular immune response, particularly the cytotoxic T lymphocyte (CTL) response. CTLs are essential for targeting and destroying infected or cancerous cells, making PCP a promising candidate for vaccines against chronic infectious diseases and cancers. This research builds on earlier studies that have highlighted the potential of various adjuvants to enhance vaccine efficacy. For instance, the application of nanotechnology has allowed for the development of nanoadjuvants that can be precisely tailored to stimulate specific immune responses[2]. Similarly, advances in our understanding of the innate immune system and its activation through pattern recognition receptors (PRRs) have paved the way for the development of new adjuvants[3]. Polysaccharides, in particular, have gained attention due to their intrinsic immunomodulatory properties, biocompatibility, and safety[4]. The study from Hebei Agricultural University contributes to this growing body of knowledge by demonstrating that natural polysaccharides like PCP can serve as effective adjuvants. By promoting both humoral and cellular immune responses, PCP addresses a critical gap in current vaccine technology. This dual-action capability is essential for developing vaccines that can provide comprehensive protection against a broader range of diseases. In summary, the research on PCP from Poria cocos offers promising insights into the development of next-generation vaccine adjuvants. By effectively stimulating both humoral and cellular immune responses, PCP has the potential to enhance vaccine efficacy significantly, particularly for chronic infectious diseases and cancers. This study not only underscores the importance of exploring new adjuvant materials but also highlights the role of polysaccharides in advancing vaccine technology.



Main Study

1) Structural characterization and adjuvant activity of a water soluble polysaccharide from Poria cocos.

Published 10th June, 2024


Related Studies

2) Tailoring inorganic nanoadjuvants towards next-generation vaccines.


3) Emerging concepts in the science of vaccine adjuvants.


4) Polysaccharides as vaccine adjuvants.


Related Articles

An unhandled error has occurred. Reload 🗙